Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease.
about
Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in ParkinsonĀ“s disease patients with motor complicationsAvailable and emerging treatments for Parkinson's disease: a reviewDepressogenic effects of medications: a reviewSide effects of a dopamine agonist therapy for Parkinson's disease: a mini-review of clinical pharmacologyA systematic review of the literature on disorders of sleep and wakefulness in Parkinson's disease from 2005 to 2015.Nonergot dopamine-receptor agonists for treating Parkinson's disease - a network meta-analysis.Dopamine agonist therapy in advanced Parkinson's diseaseEfficacy of antidepressive medication for depression in Parkinson disease: a network meta-analysis.Ropinirole in restless legs syndrome and periodic limb movement disorderDepression and Parkinson's disease: current knowledge.Improving symptom control in early Parkinson's diseaseRotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER).Neurobiology of depression and anxiety in Parkinson's diseaseSleep Duration and "on" Time during Different Periods of the Day and Night in Patients with Advanced Parkinson's Disease Receiving Adjunctive Ropinirole Prolonged Release.Nonmotor symptoms groups in Parkinson's disease patients: results of a pilot, exploratory studyHow to optimize the treatment of early stage Parkinson's disease.Nonmotor outcomes in Parkinson's disease: is deep brain stimulation better than dopamine replacement therapy?Patient considerations in early management of Parkinson's disease: focus on extended-release pramipexoleClinical aspects and management of levodopa-induced dyskinesia.Evaluation and management of the non-motor features of Parkinson's disease.The Efficacy Profile of Rotigotine During the Waking Hours in Patients With Advanced Parkinson's Disease: A Post Hoc Analysis.Treatment of Parkinson's disease in the advanced stage.Sleep and non-motor symptoms in Parkinson's disease.Non-Ergot Dopamine Agonists Do Not Increase the Risk of Heart Failure in Parkinson's Disease Patients: A Meta-Analysis of Randomized Controlled TrialsBeneficial effect of pramipexole for motor function and depression in Parkinson's disease.Role of dopamine agonists in Parkinson's disease: an update.Pharmacotherapy for Parkinson's disease.Irregular gastrointestinal drug absorption in Parkinson's disease.Motor and nonmotor complications in Parkinson's disease: an argument for continuous drug delivery?Current status of symptomatic medical therapy in Parkinson's diseaseA review of ropinirole prolonged release in Parkinson's disease.What's in the pipeline for the treatment of Parkinson's disease?Update on ropinirole in the treatment of Parkinson's disease.Neuropsychiatric symptoms in Parkinson's disease.Current strategies in the treatment of Parkinson's disease and a personalized approach to management.Twice-Daily versus Once-Daily Pramipexole Extended Release Dosage Regimens in Parkinson's Disease.Sleep disturbances in Parkinson disease and their potential role in heterogeneity.Comparison for Efficacy and Tolerability among Ten Drugs for Treatment of Parkinson's Disease: A Network Meta-Analysis.Specific patient-reported outcome measures for Parkinson's disease: analysis and applications.Pramipexole extended-release (once-daily formulation) for the treatment of Parkinson's disease.
P2860
Q24234273-5080B90A-E9AB-4603-82E8-D67B0F3B60F4Q24633444-B3F65370-2451-473B-AE3A-515CB1F62F24Q24635465-F7C50F3E-73DB-4E55-8994-45D65E87A482Q26738349-EC8D23E8-E14C-40EA-8BDB-0F87C1ED799BQ30240991-85C94271-ED13-48A8-A338-A0277D8DFC89Q33604937-96379B5E-FAE4-4359-B055-C0772BAF278CQ33636332-87EDF7C1-CBE6-48E6-A9BD-B5201C5E4062Q33765388-1B13BFAA-A022-43C1-9D1D-C7D7E91FC243Q33802191-3AE92EF0-F1F3-4AC8-81DC-7332C7745CE5Q34382560-3210420F-E50F-439E-A4AB-C820A5D2B02FQ34409267-B7113B50-D339-419C-8A14-94AFBD5B7D36Q34771200-40CF9DDD-1ABB-4E73-B7E9-3D5B99A548FBQ35028706-71F40FEA-2890-41D7-B733-55FC2B87240AQ35028804-5F11CC39-D02D-443B-8093-A00FB8CF0F6AQ35028869-321A670A-64C8-4818-B3E7-C2D296CC81A3Q35599297-CEBDE432-4A23-4DA4-AFDA-7E9C4F0293BDQ35654026-15B671C6-E463-42AE-8574-32B67BC96BA7Q35716858-6EE569CC-D314-42EE-B89C-521B3E2B0445Q36022700-5C64CE36-4B0B-4A02-B18B-74A45B4CA3B3Q36443721-E1B22CDB-CF2D-4E67-95AD-5E92A2AF90F9Q36685653-22F0AE4C-0521-4873-80DC-4783B1FDC471Q36725292-9DAB484C-7065-4D84-A183-3C559B99C7B1Q36725295-97BD01EE-C786-4E17-9BC3-F5DFBA51A9CEQ36856977-5008D821-5911-4681-A3C0-F72F31C5083DQ36876408-0AB1666F-D69B-4B56-91D9-BF2222606C21Q36972701-CE12D858-09C6-4595-838C-79B4B39E3F0CQ37016031-720F762D-245A-440A-9564-34A6BCF55727Q37076343-C8871936-7357-412B-9C54-A0E4F50FACD1Q37115650-DCA69856-8AF7-4857-A67A-D6171CE26E47Q37131229-A8FF9F2C-39B8-4679-B6A0-CFB2D495F79AQ37199938-735A4909-DCAE-4C3A-AAC7-5D87C1F78D57Q37352050-BFD0BCCF-9D53-433F-A836-BFD0273638E3Q37531960-68761C20-50A2-4F4F-AFCC-29D62B5E7889Q37600783-2665D308-DC30-48BB-A876-DCB709E69F15Q37642000-9A2EFBCD-B58F-4727-B383-2743624F2764Q37654377-7325F550-A27A-44AC-B1A2-EE9963B06BA1Q37681251-82D853D4-B344-44D3-8798-D3451253F24AQ37736512-5008836E-CEDE-4431-85EA-90CFBF142B22Q37763129-BE57CE33-4B70-4462-8017-263F4430D546Q37776519-0AC91A82-B1D9-4429-9745-2936ECD6B119
P2860
Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease.
description
2007 nĆ® lÅ«n-bĆ»n
@nan
2007幓ć®č«ę
@ja
2007幓å¦ęÆęē«
@wuu
2007幓å¦ęÆęē«
@zh
2007幓å¦ęÆęē«
@zh-cn
2007幓å¦ęÆęē«
@zh-hans
2007幓å¦ęÆęē«
@zh-my
2007幓å¦ęÆęē«
@zh-sg
2007幓åøč”ęē«
@yue
2007幓åøč”ęē«
@zh-hant
name
Ropinirole 24-hour prolonged r ...... in advanced Parkinson disease.
@en
Ropinirole 24-hour prolonged r ...... in advanced Parkinson disease.
@nl
type
label
Ropinirole 24-hour prolonged r ...... in advanced Parkinson disease.
@en
Ropinirole 24-hour prolonged r ...... in advanced Parkinson disease.
@nl
prefLabel
Ropinirole 24-hour prolonged r ...... in advanced Parkinson disease.
@en
Ropinirole 24-hour prolonged r ...... in advanced Parkinson disease.
@nl
P2093
P1433
P1476
Ropinirole 24-hour prolonged r ...... in advanced Parkinson disease.
@en
P2093
D D Truong
EASE-PD Adjunct Study Investigators
S A Factor
P304
P356
10.1212/01.WNL.0000258660.74391.C1
P407
P577
2007-04-01T00:00:00Z